GE Healthcare today announced a research collaboration agreement with Eisai Inc. for use of the GE Healthcare investigational PET amyloid imaging agent, [18F]flutemetamol, to help select patients for a phase I clinical trial being conducted by Eisai.

Specialists with Connecticut-based Oxford Performance Materials have used 3D printing technology to replace three-quarters of a man’s injured skull, according to the New York Daily News.

Chronic traumatic encephalopathy (CTE) has been blamed for a number of high profile suicides among National Football League players, but some are wondering if the degenerative brain disease could have been a factor in the Boston Marathon bombings.

While accepting that gaps in knowledge about concussions exist, the editorial board for The Lancet Neurology called for more practical guidelines for both neurologists and lay observers in managing concussions, particularly those sustained while playing sports.

Researchers have developed a method to predict how much pain people are feeling based on functional MRI (fMRI) scans, which could pave the way for an objective quantification of pain rather than relying on a patient’s self-reported level of pain, according to research published April 11 in the New England Journal of Medicine.

A new genetically engineered lab rat that has the full array of brain changes associated with Alzheimer's disease supports the idea that increases in a molecule called beta-amyloid in the brain causes the disease, according to a study, published in the Journal of Neuroscience.

Scientists at the ATR Computation Neuroscience Laboratories in Kyoto, Japan, have found a way to predict what a person is dreaming about based on fMRI scans of dreamers.

A review article published in a special issue of Nature Reviews Neurology dedicated to traumatic brain injury (TBI) came with a plea for more long-term studies and identification of genetic risk factors for permanent disability stemming from chronic traumatic encephalopathy (CTE) and Alzheimer’s disease.